These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

481 related items for PubMed ID: 19427871

  • 41. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.
    White WB, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, Fleck P, Heller S, Mehta C, Nissen SE, Perez A, Wilson C, Zannad F.
    Am Heart J; 2011 Oct; 162(4):620-626.e1. PubMed ID: 21982652
    [Abstract] [Full Text] [Related]

  • 42. Non-linear increase in GLP-1 levels in response to DPP-IV inhibition in healthy adult subjects.
    Dai H, Gustavson SM, Preston GM, Eskra JD, Calle R, Hirshberg B.
    Diabetes Obes Metab; 2008 Jun; 10(6):506-13. PubMed ID: 18284437
    [Abstract] [Full Text] [Related]

  • 43. Effects of the combination of a dipeptidyl peptidase IV inhibitor and an insulin secretagogue on glucose and insulin levels in mice and rats.
    Yamazaki K, Yasuda N, Inoue T, Yamamoto E, Sugaya Y, Nagakura T, Shinoda M, Clark R, Saeki T, Tanaka I.
    J Pharmacol Exp Ther; 2007 Feb; 320(2):738-46. PubMed ID: 17093132
    [Abstract] [Full Text] [Related]

  • 44. Dipeptidyl peptidase-4 inhibition in diabetic rats leads to activation of the transcription factor CREB in β-cells.
    Pugazhenthi S, Qin L, Bouchard R.
    Eur J Pharmacol; 2015 May 15; 755():42-9. PubMed ID: 25720341
    [Abstract] [Full Text] [Related]

  • 45. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability.
    Youn YS, Chae SY, Lee S, Jeon JE, Shin HG, Lee KC.
    Biochem Pharmacol; 2007 Jan 01; 73(1):84-93. PubMed ID: 17054919
    [Abstract] [Full Text] [Related]

  • 46. K579, a slow-binding inhibitor of dipeptidyl peptidase IV, is a long-acting hypoglycemic agent.
    Takasaki K, Iwase M, Nakajima T, Ueno K, Nomoto Y, Nakanishi S, Higo K.
    Eur J Pharmacol; 2004 Feb 23; 486(3):335-42. PubMed ID: 14985056
    [Abstract] [Full Text] [Related]

  • 47. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin.
    Capuano A, Sportiello L, Maiorino MI, Rossi F, Giugliano D, Esposito K.
    Drug Des Devel Ther; 2013 Feb 23; 7():989-1001. PubMed ID: 24068868
    [Abstract] [Full Text] [Related]

  • 48. Alogliptin (nesina) for type 2 diabetes.
    Med Lett Drugs Ther; 2013 May 27; 55(1417):41-3. PubMed ID: 23715128
    [No Abstract] [Full Text] [Related]

  • 49. Chronic administration of DSP-7238, a novel, potent, specific and substrate-selective DPP IV inhibitor, improves glycaemic control and beta-cell damage in diabetic mice.
    Furuta Y, Horiguchi M, Sugaru E, Ono-Kishino M, Otani M, Sakai M, Masui Y, Tsuchida A, Sato Y, Takubo K, Hochigai H, Kimura H, Nakahira H, Nakagawa T, Taiji M.
    Diabetes Obes Metab; 2010 May 27; 12(5):421-30. PubMed ID: 20415690
    [Abstract] [Full Text] [Related]

  • 50. Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors.
    Tahara A, Matsuyama-Yokono A, Nakano R, Someya Y, Hayakawa M, Shibasaki M.
    Pharmacol Rep; 2009 May 27; 61(5):899-908. PubMed ID: 19904014
    [Abstract] [Full Text] [Related]

  • 51. Alogliptin; a review of a new dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes mellitus.
    Said S, Nwosu AC, Mukherjee D, Hernandez GT.
    Cardiovasc Hematol Disord Drug Targets; 2014 May 27; 14(1):64-70. PubMed ID: 24993124
    [Abstract] [Full Text] [Related]

  • 52. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.
    Moritoh Y, Takeuchi K, Hazama M.
    J Pharmacol Exp Ther; 2009 May 27; 329(2):669-76. PubMed ID: 19208898
    [Abstract] [Full Text] [Related]

  • 53. Alogliptin: safety, efficacy, and clinical implications.
    Marino AB, Cole SW.
    J Pharm Pract; 2015 Feb 27; 28(1):99-106. PubMed ID: 24532820
    [Abstract] [Full Text] [Related]

  • 54. [Alogliptin (Vipidia): a selective DPP-4 inhibitor with a good cardiovascular safety].
    Scheen AJ.
    Rev Med Liege; 2014 Feb 27; 69(7-8):460-6. PubMed ID: 25158388
    [Abstract] [Full Text] [Related]

  • 55. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study.
    DeFronzo RA, Fleck PR, Wilson CA, Mekki Q, Alogliptin Study 010 Group.
    Diabetes Care; 2008 Dec 27; 31(12):2315-7. PubMed ID: 18809631
    [Abstract] [Full Text] [Related]

  • 56. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects.
    Herman GA, Bergman A, Liu F, Stevens C, Wang AQ, Zeng W, Chen L, Snyder K, Hilliard D, Tanen M, Tanaka W, Meehan AG, Lasseter K, Dilzer S, Blum R, Wagner JA.
    J Clin Pharmacol; 2006 Aug 27; 46(8):876-86. PubMed ID: 16855072
    [Abstract] [Full Text] [Related]

  • 57. Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical practice.
    Bohannon N.
    Postgrad Med; 2009 Jan 27; 121(1):40-5. PubMed ID: 19179812
    [Abstract] [Full Text] [Related]

  • 58. Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Gallwitz B.
    IDrugs; 2008 Dec 27; 11(12):906-17. PubMed ID: 19051153
    [Abstract] [Full Text] [Related]

  • 59. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism.
    Ahrén B, Foley JE.
    Int J Clin Pract Suppl; 2008 Mar 27; (159):8-14. PubMed ID: 18269436
    [Abstract] [Full Text] [Related]

  • 60. Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin.
    White WB, Wilson CA, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, Heller SK, Mehta CR, Nissen SE, Zannad F, Kupfer S, EXAMINE Investigators.
    Hypertension; 2016 Sep 27; 68(3):606-13. PubMed ID: 27480840
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.